HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Natrol Alternative Kava Supplement, New Labeling Debuts At Expo West

This article was originally published in The Tan Sheet

Executive Summary

New labeling for Natrol's full lineup of dietary supplements will be in place by late August or early September, the firm said

You may also be interested in...

Natrol Carb Intercept Ad Claims Require Further Scientific Backing – NAD

Natrol should discontinue claims that its Carb Intercept Phase 2 starch blocker is "scientifically proven to neutralize starch," according to the National Advertising Division

Perrigo New Products Include Branded Weight-Loss Supplement, Kid’s Multi

Perrigo introduced two branded products developed in-house at the National Association of Chain Drug Stores Marketplace June 8-10: Dr. Steven Rosenblatt's Ephedra Free Starch Blocker with Phase 2 Starch Neutralizer and Sesame Street Complete Children's Multivitamin Multimineral Supplement

Chattem Exiting Ephedra Market With Dexatrim Reformulations

Chattem is getting out of the ephedra business and is set to ship three reformulated Dexatrim SKUs by the end of September

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts